Robertson, Australia

Michael Gerometta

USPTO Granted Patents = 3 

 

 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2017-2024

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Michael Gerometta: Innovator in Ligand Binding Molecules

Introduction

Michael Gerometta is a notable inventor based in Robertson, Australia. He has made significant contributions to the field of biotechnology, particularly in the development of ligand binding molecules. With a total of three patents to his name, Gerometta's work focuses on modulating angiogenesis and lymphangiogenesis, which are critical processes in various biological functions.

Latest Patents

Gerometta's latest patents include innovative approaches to ligand binding molecules. One of his inventions is directed to ligand binding molecules and their uses to modulate angiogenesis and/or lymphangiogenesis. Another patent focuses on polynucleotides that encode VEGFR-3 ligand binding molecules, which also aim to modulate these vital processes. Additionally, he has modified a glycosylation sequon of wildtype VEGFR-3 to eliminate glycosylation in the encoded ligand binding molecules, enhancing their functionality.

Career Highlights

Throughout his career, Michael Gerometta has been associated with Vegenics Pty Limited, where he has been able to apply his expertise in biotechnology. His work has contributed to advancements in therapeutic applications, particularly in the treatment of diseases related to blood vessel formation.

Collaborations

Gerometta collaborates with Timothy Edward Adams, a fellow innovator in the field. Their partnership has fostered a productive environment for research and development, leading to significant advancements in their respective areas of expertise.

Conclusion

Michael Gerometta's contributions to the field of ligand binding molecules exemplify the impact of innovation in biotechnology. His patents reflect a commitment to advancing medical science and improving therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…